<DOC>
	<DOCNO>NCT01871415</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled study evaluate efficacy , safety tolerability aleglitazar combination metformin patient Type 2 diabetes mellitus inadequately control metformin monotherapy . Patients randomize receive either aleglitazar 150 mcg orally daily placebo 26 week combination pre-existing metformin regimen dose .</brief_summary>
	<brief_title>A Study Aleglitazar Combination With Metformin Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Type 2 diabetes mellitus treat stable metformin monotherapy least 12 week prior screen ; metformin dose &gt; /= 1500 mg/day ( individual maximum tolerate dose ) , maximum dose specify label HbA1c &gt; /= 7 % &lt; /= 9.5 % screen within 4 week prior screen prerandomization visit Fasting plasma glucose &lt; /= 13.3 mmol/L ( &lt; /= 240 mg/dL ) prerandomization visit Agreement maintain diet exercise habit implement runin phase full course study Pregnant woman , woman intend become pregnant study period , currently lactate woman , woman childbearing potential use highly effective , medically approve birth control method Diagnosis history : 1 . Type 1 diabetes mellitus , diabetes result pancreatic injury , secondary form diabetes 2 . Acute metabolic diabetic complication ketoacidosis hyperosmolar coma within past 6 month Any previous treatment thiazolidinedione dual PPAR agonist Any body weight lower lipoproteinmodifying therapy ( e.g . fibrates ) within 12 week prior screen exception stable ( &gt; = 1 month ) statin therapy Prior intolerance fibrate Treatment antidiabetic medication metformin last 12 week prior screen Triglycerides ( fast ) &gt; 4.5 mmol/L ( &gt; 400 mg/dL ) screening within 4 week prior screen Clinically apparent liver disease Anemia within 4 week prior screen Inadequate renal function Symptomatic congestive heart failure NYHA Class IIIV screen Myocardial infarction , acute coronary syndrome transient ischemic attack/stroke within 6 month prior screen visit Known macular edema screen prior screen visit Diagnosed and/or treat malignancy ( except basal cell skin cancer , situ carcinoma cervix , situ prostate cancer ) within past 5 year Uncontrolled hypertension History active substance abuse ( include alcohol ) within past 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>